Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUTL Autolus Therapeutics	$1.50 -4.5%	$2.22	$1.11 ▼ $5.00	$399.21M	1.9	2.84 million shs	2.14 million shs
CRVS Corvus Pharmaceuticals	$5.74 +6.1%	$4.52	$2.54 ▼ $10.00	$427.71M	0.42	521,085 shs	557,521 shs
HLVX HilleVax	$2.09 +0.5%	$2.07	$1.34 ▼ $2.17	$104.79M	0.77	1.15 million shs	168,590 shs
IMAB I-Mab	$4.16 -2.1%	$3.03	$0.60 ▼ $5.90	$339.71M	1.38	4.86 million shs	1.40 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUTL Autolus Therapeutics	0.00%	-14.29%	-37.50%	-13.79%	-61.73%
CRVS Corvus Pharmaceuticals	0.00%	+3.42%	+37.65%	+51.05%	+40.00%
HLVX HilleVax	0.00%	+1.46%	-0.95%	+13.28%	+9.42%
IMAB I-Mab	0.00%	-18.27%	+106.97%	+220.00%	+255.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUTL Autolus Therapeutics	2.6899 of 5 stars	3.5	1.0	3.0	3.3	0.6
CRVS Corvus Pharmaceuticals	3.1581 of 5 stars	3.5	2.0	3.7	3.3	0.6
HLVX HilleVax	1.6634 of 5 stars	1.0	4.0	2.7	3.3	1.3
IMAB I-Mab	2.955 of 5 stars	3.5	5.0	2.8	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUTL Autolus Therapeutics	3.00	Buy	$9.12	508.00% Upside
CRVS Corvus Pharmaceuticals	3.00	Buy	$15.00	161.32% Upside
HLVX HilleVax	2.00	Hold	$2.00	-4.31% Downside
IMAB I-Mab	3.00	Buy	$7.00	68.27% Upside

Current Analyst Ratings Breakdown

Latest HLVX, CRVS, AUTL, and IMAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/28/2025	IMAB I-Mab	Loop Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$8.00
8/28/2025	IMAB I-Mab	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/21/2025	IMAB I-Mab	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
8/20/2025	IMAB I-Mab	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$5.00 ➝ $6.00
8/13/2025	AUTL Autolus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$6.00 ➝ $5.00
8/8/2025	HLVX HilleVax	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
7/21/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
7/9/2025	IMAB I-Mab	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/9/2025	IMAB I-Mab	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
6/27/2025	IMAB I-Mab	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $5.00
6/12/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00

(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUTL Autolus Therapeutics	$10.12M	39.45	N/A	N/A	$1.30 per share	1.15
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	$1.08 per share	N/A
HLVX HilleVax	N/A	N/A	N/A	N/A	$2.95 per share	N/A
IMAB I-Mab	$3.89M	87.33	N/A	N/A	$2.41 per share	1.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUTL Autolus Therapeutics	-$220.66M	-$0.84	N/A	N/A	N/A	N/A	-56.18%	-29.61%	11/11/2025 (Estimated)
CRVS Corvus Pharmaceuticals	-$62.29M	-$1.01	N/A	N/A	N/A	N/A	-28.61%	-18.05%	11/11/2025 (Estimated)
HLVX HilleVax	-$147.27M	-$1.43	N/A	N/A	N/A	N/A	-34.29%	-28.50%	11/6/2025 (Estimated)
IMAB I-Mab	-$22.23M	N/A	0.00	N/A	N/A	N/A	-19.65%	-18.58%	11/13/2025 (Estimated)

Latest HLVX, CRVS, AUTL, and IMAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/20/2025	Q2 2025	IMAB I-Mab	-$0.10	-$0.07	+$0.03	-$0.07	N/A	N/A
8/12/2025	Q2 2025	AUTL Autolus Therapeutics	-$0.24	-$0.18	+$0.06	-$0.18	$12.92 million	$13.50 million
8/7/2025	Q2 2025	CRVS Corvus Pharmaceuticals	-$0.13	-$0.10	+$0.03	-$0.10	N/A	N/A
8/6/2025	Q2 2025	HLVX HilleVax	-$0.14	-$0.11	+$0.03	-$0.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HLVX HilleVax	N/A	N/A	N/A	N/A	N/A
IMAB I-Mab	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUTL Autolus Therapeutics	N/A	8.43	8.07
CRVS Corvus Pharmaceuticals	N/A	8.91	8.91
HLVX HilleVax	N/A	26.39	26.39
IMAB I-Mab	N/A	22.82	22.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUTL Autolus Therapeutics	72.83%
CRVS Corvus Pharmaceuticals	46.64%
HLVX HilleVax	86.42%
IMAB I-Mab	38.38%

Insider Ownership

Company	Insider Ownership
AUTL Autolus Therapeutics	25.70%
CRVS Corvus Pharmaceuticals	28.50%
HLVX HilleVax	24.90%
IMAB I-Mab	22.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUTL Autolus Therapeutics	330	266.14 million	197.74 million	Optionable
CRVS Corvus Pharmaceuticals	30	74.51 million	53.28 million	Optionable
HLVX HilleVax	20	50.14 million	37.66 million	Not Optionable
IMAB I-Mab	380	81.66 million	63.61 million	Optionable

HLVX, CRVS, AUTL, and IMAB Headlines

Recent News About These Companies

I-Mab Insiders Land Bargain With Gains Of US$5.0m

5 hours ago | finance.yahoo.com

Are You Looking for a Top Momentum Pick? Why I-Mab Sponsored ADR (IMAB) is a Great Choice

August 28 at 1:00 PM | zacks.com

Stonepine Capital Management LLC Makes New $398,000 Investment in I-Mab Sponsored ADR $IMAB

August 26, 2025 | marketbeat.com

HC Wainwright Issues Positive Forecast for I-Mab Earnings

August 26, 2025 | americanbankingnews.com

HC Wainwright Comments on I-Mab's Q3 Earnings (NASDAQ:IMAB)

August 26, 2025 | marketbeat.com

I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee

August 25, 2025 | globenewswire.com

I-Mab (NASDAQ:IMAB) Upgraded by Wall Street Zen to "Buy" Rating

August 25, 2025 | marketbeat.com

Needham & Company LLC Forecasts Strong Price Appreciation for I-Mab (NASDAQ:IMAB) Stock

August 23, 2025 | marketbeat.com

I-Mab's (IMAB) Buy Rating Reiterated at HC Wainwright

August 23, 2025 | marketbeat.com

I-Mab (NASDAQ:IMAB) Announces Earnings Results, Beats Estimates By $0.03 EPS

August 22, 2025 | marketbeat.com

I-Mab's (IMAB) "Buy" Rating Reiterated at HC Wainwright

August 22, 2025 | americanbankingnews.com

I-Mab Biopharma: I-Mab Reports Second Quarter 2025 Financial Results and Provides Business Update

August 21, 2025 | finanznachrichten.de

I-Mab to Participate in September Investor Conferences

August 21, 2025 | globenewswire.com

I-Mab (IMAB) Expected to Announce Earnings on Wednesday

August 21, 2025 | marketbeat.com

I-Mab Reports Second Quarter 2025 Financial Results and Provides Business Update

August 20, 2025 | tmcnet.com

I-Mab price target raised to $6 from $5 at Needham

August 20, 2025 | msn.com

I-Mab Reports Strong Financials and Clinical Progress in August 2025

August 20, 2025 | msn.com

I MAB (ADS) options imply 11.8% move in share price post-earnings

August 19, 2025 | msn.com

Ground Swell Capital LLC Takes Position in I-Mab Sponsored ADR (NASDAQ:IMAB)

August 17, 2025 | marketbeat.com

I-Mab (NASDAQ:IMAB) Trading 14.1% Higher - Here's Why

August 12, 2025 | marketbeat.com

I-Mab Completes Enrollment in Planned Phase 1b Dose Expansion Study for Givastomig in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers

August 11, 2025 | taiwannews.com.twT

New MarketBeat Followers Over Time

Media Sentiment Over Time

HLVX, CRVS, AUTL, and IMAB Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

$1.50 -0.07 (-4.46%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$1.50 +0.00 (+0.33%)

As of 08/29/2025 07:49 PM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Corvus Pharmaceuticals NASDAQ:CRVS

$5.74 +0.33 (+6.10%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$5.68 -0.06 (-1.05%)

As of 08/29/2025 07:44 PM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

HilleVax NASDAQ:HLVX

$2.09 +0.01 (+0.48%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$2.08 0.00 (-0.24%)

As of 08/29/2025 06:52 PM Eastern

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

I-Mab NASDAQ:IMAB

$4.16 -0.09 (-2.12%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$4.24 +0.08 (+1.80%)

As of 08/29/2025 07:27 PM Eastern

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time